Overview
AI-driven health management tools can leverage continuous glucose monitoring (CGM), physical activity, and dietary data to provide real-time, individualized feedback, improving self-management and adherence. The X Life model integrates AI algorithms with wearable devices to dynamically adjust dietary and exercise recommendations. Preliminary user studies suggest good usability and user experience, with potential to promote positive behavior change.
This trial aims to preliminarily evaluate whether the X Life AI system combined with CGM management can improve glucose tolerance (measured by oral glucose tolerance test [OGTT] incremental area under the curve [iAUC]) in adults with prediabetes, providing effect size and protocol design reference for a future confirmatory randomized controlled trial.
Eligibility
Inclusion Criteria:
- Age 18-70 years
- Prediabetes (per ADA or WHO criteria)
- Stable lifestyle and body weight (±5%) for ≥3 months
- Owns and can operate a smartphone
- Able to understand and sign informed consent
Exclusion Criteria:
- Current glucose-lowering medication use
- Severe cardiovascular disease, liver/kidney dysfunction, or active malignancy
- Psychiatric or cognitive disorders affecting participation
- Planned major surgery or long-distance travel during the study
- Allergy/intolerance to CGM sensor materials